MiMedx GroupMDXG -0.39%57 Net Margin % is -18.41% as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, MiMedx Group ranks better than 79.28% on this metric.
Net margin is calculated as Net Income divided by its Revenue. MiMedx Group's Net Income for the
three
months ended in Mar. 2026 was $-10.9 Mil. MiMedx Group's Revenue for the
three
months ended in Mar. 2026 was $59.0 Mil. Therefore, MiMedx Group's net margin for the quarter that ended in Mar. 2026 was -18.41%.
The historical rank and industry rank for MiMedx Group's Net Margin % or its related term are showing as below:
MDXG'
s Net Margin % Range Over the Past 10 Years
Min: -19.85 Med: -2.45 Max: 20.16
Current: 7.88
MDXG's Net Margin % is ranked better than 79.28% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs MDXG: 7.88
MiMedx Group (NAS:MDXG) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
MiMedx Group Net Margin % Related Terms
MiMedx Group Net Margin % Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiMedx Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Net Margin % of -18.41% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on MiMedx Group and its competitors. According to the industry distribution chart, MiMedx Group ranks #196 out of 946 companies in the Biotechnology industry, placing it in the top 20.7%.
Is MiMedx Group's Net Margin % too high?
MiMedx Group's current Net Margin % is -18.41%. Based on the distribution chart, MiMedx Group ranks #196 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Net Margin % compare to ASMB and AGMB?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #196 out of 946 companies for Net Margin %. This places MiMedx Group in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on MiMedx Group and its competitors. MiMedx Group's current Net Margin % is -18.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.82 — trading 45.2% below its estimated fair value. The current Net Margin % is -18.41%. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Net Margin % is -18.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.82 is trading 45.2% below its estimated GF Value™ of $6.96.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Net Margin %: -18.41%
GF Value™: $6.96 vs. price of $3.82 (45.2% below fair value)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
